Liver

Tocotrienols support Liver Health by reducing Fat Accumulation, Inflammation, Oxidative Stress, Fibrosis, and even Cancer risk. 

  • Annatto-derived Delta- & Gamma- Tocotrienols (200–300 mg/day, 12–24 weeks) improved liver enzymes and reduced hepatic fat in NAFLD (Non-Alcoholic Fatty Liver Disease) in human clinical trial patients.

  • Delta- and Gamma- Tocotrienols cause reductions in liver enzymes (ALT, AST), liver fat content, and Inflammation markers. They improve Insulin Sensitivity, which is key in metabolic liver disease.

  • Tocotrienols downregulate NF-κB and pro-inflammatory Cytokines (TNF-α, IL-6). This reduces Chronic Liver Inflammation that contributes to Fibrosis and Cirrhosis progression. 

  • Tocotrienols are potent antioxidants and protect Hepatocytes (liver cells) from Lipid Peroxidation (rusting) and Mitochondrial damage.

  • Tocotrienols suppress Hepatic Stellate Cell activation, slowing Fibrosis. They show anti-tumor effects in liver cancer studies (Hepatocellular Carcinoma), reducing Angiogenesis (formation of new blood vessels that feed the cancer) and promoting Apoptosis (programmed cell death) of malignant cancer cells. 

  •  Tocotrienols naturally suppress HMG-CoA reductase (the same enzyme targeted by Statins). This lowers Cholesterol and Triglyceride levels, indirectly benefiting Liver function. 

  • Tocotrienols reduce Fibrosis, improved Antioxidant status, and lower Inflammation in liver injury animal models. 

  • Tocotrienols protected Hepatocytes (liver cells) from Oxidative Stress and Apoptosis.

References

Anticancer Activity of Delta-Tocotrienol in Human Hepatocarcinoma: Involvement of Autophagy Induction (2024) https://pmc.ncbi.nlm.nih.gov/articles/PMC11311296/?utm_source=chatgpt.com

Assessing the efficacy of Tocotrienol-rich fraction vitamin E in obese children with Non-Alcoholic Fatty Liver Disease: a single-blind, randomized clinical trial (2024) 

https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-024-04993-8?utm_source=chatgpt.com 

Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review (2023) https://pmc.ncbi.nlm.nih.gov/articles/PMC9965814/?utm_source=chatgpt.com

Revisiting the Therapeutic Potential of Tocotrienol (2022)

https://pmc.ncbi.nlm.nih.gov/articles/PMC9544065/?utm_source=chatgpt.com

Comparison of Delta-Tocotrienol and Alpha- Tocopherol effects on Hepatic Steatosis and inflammatory biomarkers in patients with Non-Alcoholic Fatty Liver Disease: A randomized double-blind active-controlled trial (2022) https://www.sciencedirect.com/science/article/pii/S0965229922000681?utm_source=chatgpt.com

Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents (2021)

https://pmc.ncbi.nlm.nih.gov/articles/PMC8295474/?utm_source=chatgpt.com

Delta- Tocotrienol supplementation improves biochemical markers of Hepatocellular injury and Steatosis in patients with Non-Alcoholic Fatty Liver Disease: A randomized, placebo-controlled trial (2020)  https://pubmed.ncbi.nlm.nih.gov/32951743/

Regulation of inflammatory response and Oxidative Stress by Tocotrienol in a rat model of Non-Alcoholic Fatty Liver Disease (2020)

https://www.sciencedirect.com/science/article/pii/S1756464620304333?utm_source=chatgpt.com

Effects of Delta- Tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease (2018)

https://pmc.ncbi.nlm.nih.gov/articles/PMC6284694/?utm_source=chatgpt.com